Margetuximab is developed and produced by which pharmaceutical company

Margetuximab (margetuximab-cmkb) is an innovative humanized monoclonal antibody, mainly used to treat HER2-positive breast cancer and other solid tumors. The drug was developed by MacroGenics, an American biopharmaceutical company, a biotechnology company focused on immuno-oncology and antibody engineering. MacroGenics leverages its proprietary Fc engineering technology to optimize anti-HER2 monoclonal antibodies to enhance their immune effector functions, thereby enhancing anti-tumor activity. In 2019, margituximab received accelerated approval from the U.S. Food and Drug Administration (FDA) for use in patients with metastatic breast cancer who have previously received at least two anti-HER2 treatment regimens.

Subsequently, Acer reached a cooperation with the pharmaceutical company Pfizer, which is responsible for the global commercial promotion and production of margituximab. Pfizer has ensured the quality and broad accessibility of the drug with its comprehensive global production and supply chain system. Pfizer has profound R&D and marketing experience in the field of anti-cancer drugs, which provides a solid guarantee for the promotion and clinical application of margituximab. In addition, Pfizer and MacroGenics are jointly conducting multiple clinical trials to explore the potential of margetuximab in other tumor types and combination treatments.

In terms of production technology, magituximab uses modern biopharmaceutical technology and is produced in mammalian cells through a recombinantDNA expression system, ensuring its high purity and stability. The production process strictly abides by international good manufacturing practices (GMP) to ensure the consistency and safety of drugs. Pfizer's manufacturing facilities are equipped with advanced equipment and quality control systems to meet global demand for the drug.

Reference materials:https://www.margenza.com/